Amcor
Scale and cash flow meet commodity reality after a transformational merger
Amcor is now the world’s largest consumer and healthcare packaging platform following its all‑stock combination with Berry Global on April 30, 2025. The enlarged business has unmatched global scale across flexibles, rigid packaging, closures and dispensing, with management targeting 650 million dollars of pre‑tax synergies by fiscal 2028 and free cash flow of 1.8 to 1.9 billion dollars in fiscal 2026. Fiscal 2025 reported adjusted free cash flow was 926 million dollars, net debt stood at 13.3 billion dollars and leverage around 3.5x on a combined basis, with a glidepath to 3.1 to 3.2x by June 2026. The investment case rests on durable cost advantages from scale procurement and a wide portfolio, reasonable predictability from staples and healthcare end markets, and self‑help from synergies and portfolio optimization.
Offsetting this, pricing power is modest because many contracts pass through resin and other input costs with a lag, the industry is competitive, leverage is not trivial, and regulatory forces around plastics and EPR can pressure mix and costs. On balance this looks like a solid, cash‑generative compounder but not a classic high‑moat tollbooth.
Our quality view is positive but measured, and our valuation discipline anchors to TTM free cash flow per share. Note Amcor is listed on the NYSE under AMCR and on the ASX under AMC.
Does Amcor have a strong competitive moat?
Primary advantages are scale procurement, broad manufacturing footprint near customers, and a more complete multi‑format portfolio post‑merger that deepens relationships with global CPG and healthcare clients. Healthcare and certain dispensing formats carry testing and regulatory qualification that raise switching costs relative to commodity films.
Efficient scale applies in some local markets where capacity additions would depress returns. These are durable but not indestructible advantages given intense competition, limited IP barriers and customer bargaining power. Morningstar categorizes Amcor as narrow moat on cost advantages, consistent with our view.
Key erosion risks include resin cost spikes outpacing pass‑through, sustainability regulation that shifts materials mix, and private‑label price pressure.
Does Amcor have pricing power in its industry?
Contract structures often include pass‑through mechanisms for resins, films, paper and aluminum, which helps protect dollar margins over time but caps true pricing power and can introduce lag risk.
Mix improvements toward healthcare, dispensing and advanced solutions help, yet structural over‑earning from price is unlikely in a competitive, spec‑like industry. Management has acknowledged North America beverage headwinds and is reviewing non‑core assets, which underscores limited ability to price through inefficiencies.
Overall we see modest pricing power with pockets of strength.
How predictable is Amcor's business?
End‑market exposure skews to food, beverage, pharma and personal care, creating recurring volumes and relatively stable cash generation through cycles. The enlarged portfolio diversifies by customer and region, while synergy schedules and published outlooks add visibility.
FY26 guidance calls for 12 to 17 percent EPS growth and FCF roughly doubling versus FY25, driven largely by self‑help rather than an aggressive macro recovery assumption. Predictability is above average for a manufacturer, though not at the level of payment networks or data monopolies.
Is Amcor financially strong?
At June 30, 2025 net debt was 13.3 billion dollars, with combined leverage near 3.5x on management’s EBITDA estimate. The company targets 3.1 to 3.2x by June 2026 through synergy capture and cash generation. Cash interest is material, but coverage is supported by diversified cash flows and a strong investment grade profile historically.
Liquidity includes access to the bond and CP markets, and the company has been exchanging notes to optimize the stack. Balance sheet is serviceable but not fortress, so execution on deleveraging is important.
How effective is Amcor's capital allocation strategy?
Track record includes the successful 2019 Bemis integration, steady dividend growth and opportunistic portfolio actions. The Berry transaction is a large swing that we judge rational given synergy potential and portfolio adjacency, though integration complexity and leverage are elevated.
FY26 capital plan prioritizes deleveraging over repurchases, capex of 850 to 900 million dollars focused on higher value categories, and targeted divestment or restructuring of roughly 2.5 billion dollars of non‑core sales including North America beverage.
SBC is modest relative to cash earnings and buybacks have been de‑emphasized during the integration.
Does Amcor have high-quality management?
CEO Peter Konieczny is a long‑tenured Amcor operator with deep flexibles, R&D and procurement experience who led as interim CEO before appointment in September 2024. In October 2025 Amcor appointed Stephen R. Scherger, a seasoned packaging CFO from Graphic Packaging, which should strengthen integration discipline and capital allocation.
The team has articulated clear synergy milestones, FCF priorities and leverage targets. Governance reflects a global board with Berry representation post‑deal. Alignment is solid, though not founder‑led.
Is Amcor a quality company?
Amcor is an average quality company with a quality score of 66/100
- Transformational scale after closing the Berry Global deal with 650 million dollars of identified synergies within three years and an FY26 FCF guide of 1.8 to 1.9 billion dollars.
- TTM adjusted free cash flow of 926 million dollars and net debt of 13.3 billion dollars at June 30, 2025 imply leverage of about 3.5x and a deleveraging plan to near 3.1 to 3.2x by June 2026.
- Moat driven mainly by scale cost advantages and switching costs in regulated healthcare categories, but industry pricing remains largely input pass‑through with timing lags.
- Management refresh adds experienced operators at CEO and CFO, with explicit focus on synergy capture and portfolio optimization.
- Valuation discipline: TTM FCF per share is about 0.40 dollars on 2.305 billion shares; a 13x FCF multiple implies a fair value near 5.2 dollars, with upside if FY26 FCF delivery is achieved. Risk‑free 10‑year near 4.1 percent supports a required mid‑single‑digit FCF spread.
What is the fair value of Amcor stock?
Is Amcor a good investment at $47?
The following analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment advice, or a recommendation to buy or sell any security. The opinions expressed are based on publicly available information and historical data. Beanvest and its contributors may hold positions in the securities mentioned. Investors should conduct their own due diligence or consult a licensed financial advisor before making any investment decision.